Teva's subcutaneous reslizumab misses in Phase III for OCS-dependent asthma

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) reported top-line data from a Phase III trial in 177 patients with oral corticosteroid (OCS)-dependent asthma and elevated blood eosinophils showing that 110 mg subcutaneous reslizumab

Read the full 330 word article

User Sign In